INS and type 2 diabetes mellitus: New oral antidiabetic medications, known as sodium–glucose co-transporter 2 inhibitors (SGLT2 I) can effectively treat type 2 diabetes mellitus (T2DM) by increasing renal glucose excretion through an insulin-independent mechanism (Frampton, 2018).